TABLE 1.
Most common JAKis: their preferential targets and diseases where they are on market/in clinical trials.
| Name | Selectivity | Diseases |
|---|---|---|
| Ruxolitinib | JAK1, 2 | Myelofibrosis; polycythemia vera; essential thrombocythemia; myelodysplastic syndrome; acute and chronic leukemias; MM; B-cell and Hodgkin’s lymphoma; prostate, pancreatic, and BC; psoriasis; RA |
| Tofacitinib | PAN JAK | Rheumatoid psoriatic and juvenile idiopathic arthritis, ankylosing spondylitis, dry eye, renal transplant, ulcerative colitis, psoriasis, dermatitis |
| Baricitinib | JAK1,2 | RA, diabetic kidney disease, autoinflammatory syndromes |
| Lestaurtinib | AK1/JAK2,3, FLT3, TrkA/B/C | Myelofibrosis, neuroblastoma, psoriasis, MM |
| Pacritinib | JAK1, FLT3 | Myelofibrosis, myelodysplastic syndrome, leukemia, lymphoma |
| Momelotinib | JAK1,2, CDK2 | Myelofibrosis, pancreatic cancer |
| Fedratinib | JAK2 | Myelofibrosis, solid tumors, renal impairment, hepatic impairment |
| Filgotinib | JAK1 | RA, Crohn’s disease, urinary incontinence |
| Decernotinib | JAK1,2 | RA |
| Gandotinib | JAK2 | Myelofibrosis |
| AZD1480 | JAK2 | Myelofibrosis, solid tumors |